$0.88
5.93% yesterday
NYSE, Nov 15, 10:00 pm CET
ISIN
US14216R1014
Symbol
CARM
Sector
Industry

Carisma Therapeutics Stock price

$0.88
-0.07 7.01% 1M
-0.52 36.91% 6M
-2.05 69.86% YTD
-1.68 65.50% 1Y
-1.23 58.26% 3Y
-1.14 56.44% 5Y
-18.72 95.50% 10Y
NYSE, Closing price Fri, Nov 15 2024
-0.06 5.93%
ISIN
US14216R1014
Symbol
CARM
Sector
Industry

Key metrics

Market capitalization $39.20m
Enterprise Value $15.64m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.77
P/S ratio (TTM) P/S ratio 1.93
P/B ratio (TTM) P/B ratio negative
Dividend yield 0.00%
Last dividend (FY23) $5.15
Revenue growth (TTM) Revenue growth 90.67%
Revenue (TTM) Revenue $20.27m
EBIT (operating result TTM) EBIT $-66.77m
Free Cash Flow (TTM) Free Cash Flow $-68.49m
Cash position $26.88m
EPS (TTM) EPS $-1.56
P/E forward negative
P/S forward 1.83
EV/Sales forward 0.73
Short interest 2.58%
Show more

Is Carisma Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Carisma Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Carisma Therapeutics forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Carisma Therapeutics forecast:

Buy
100%

Financial data from Carisma Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
20 20
91% 91%
100%
- Direct Costs 4.77 4.77
125% 125%
24%
16 16
82% 82%
76%
- Selling and Administrative Expenses 14 14
44% 44%
69%
- Research and Development Expense 64 64
14% 14%
313%
-62 -62
14% 14%
-306%
- Depreciation and Amortization 4.77 4.77
125% 125%
24%
EBIT (Operating Income) EBIT -67 -67
10% 10%
-329%
Net Profit -64 -64
13% 13%
-315%

In millions USD.

Don't miss a Thing! We will send you all news about Carisma Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Carisma Therapeutics Stock News

Neutral
PRNewsWire
8 days ago
New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma (HCC) PHILADELPHIA , Nov. 8, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced positive pre-clin...
Neutral
PRNewsWire
9 days ago
Initial results from the Phase 1 study of CT-0525, lead product candidate, expected in the first quarter of 2025 Nomination of a development candidate for liver fibrosis program expected in the first quarter of 2025 New preclinical efficacy data from the anti-GPC3 in vivo CAR-M therapy to be presented on November 8 at SITC 2024 Annual Meeting New preclinical efficacy data in liver fibrosis to b...
Neutral
PRNewsWire
10 days ago
Pre-clinical data demonstrate robust anti-tumor activity and a novel off-the-shelf approach for GPC3+ solid tumors PHILADELPHIA , Nov. 5, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the upcoming presentation of new pre-clini...
More Carisma Therapeutics News

Company Profile

Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in 2016 and is headquartered in Philadelphia, PA.

Head office United States
CEO Steven Kelly
Employees 107
Founded 2016
Website carismatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today